Compare Bristol-Myers Squibb Co (BMY) vs Cenovus Energy Inc (CVE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Cenovus Energy Inc — how do they compare? Bristol-Myers Squibb Co trades at $58.42 (market cap $116.30B), while Cenovus Energy Inc trades at $27.17 (market cap $50.90B). The key difference: Bristol-Myers Squibb Co is far larger — about 2.3× Cenovus Energy Inc's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | CVE | |
|---|---|---|
Market Cap | $116.30B | $50.90B |
Sector | Health | Energy |
52-Week High | $62.37 | $31.80 |
52-Week Low | $42.60 | $13.96 |
Enterprise Value | $152.24B | $58.77B |
Dividend Yield | 4.42% | 2.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Cenovus Energy (CVE) trades at $27.61, up 4.58% with strong bullish technical indicators and consistent earnings beats. The stock shows solid fundamentals with a P/E of 15.62, ROE of 14.86%, and improving cash flow projections. Recent news highlights benefits from rising crude prices and operational synergies from MEG Energy acquisition.
CVE presents a compelling investment case with attractive valuation, strong profitability metrics, and positive analyst sentiment (40.74% buy ratings). Key risks include oil price volatility and execution challenges in growth projects. The integrated business model provides resilience across energy cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →
